The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1106
June 11, 2001
View Complete Issue         Table of Contents 2019 
Gleevec (STI-571) For Chronic Myeloid Leukemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Gleevec (STI-571) For Chronic Myeloid Leukemia
June 11, 2001 (Issue: 1106)
Imatinib mesylate (STI-571; Gleevec - Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of all phases of chronic myeloid leukemia (CML) after interferon has failed.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Gleevec (STI-571) For Chronic Myeloid Leukemia
Article code: 1106a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.